House Legislation Proposes Dedicated Tariff Classifications for Breast Cancer Survivors’ Prosthetics and Bras

Last updated: August 25, 2026

NewsWK — Federal lawmakers have introduced trade legislation designed to update the national tariff schedule to specifically recognize essential medical prosthetics and specialized garments for breast cancer survivors. The proposal, introduced as House Resolution 10147, directs federal authorities to modify the Harmonized Tariff Schedule of the United States by creating distinct classification codes for silicone prosthetics and mastectomy bras.

Under current trade frameworks, goods entering the country are categorized under broad tariff subheadings. H.R. 10147 proposes adding specific subheadings under Chapter 39 to cover silicone prosthetics designed for women who are breast cancer survivors, alongside dedicated provisions under Chapter 90 to categorize mastectomy bras.

Why it matters here

For millions of families and breast cancer survivors across the United States, managing post-operative care involves significant ongoing expenses for specialized medical equipment, fittings, and daily-wear essentials. Tariff classifications play a crucial role in determining the customs treatment, regulatory compliance standards, and overall supply-chain costs associated with imported medical items.

When specialized health products lack dedicated tariff lines, they are often grouped into general merchandise categories, which can expose them to inconsistent administrative burdens, unclear duty rates, and regulatory delays at ports of entry. Creating explicit tariff definitions allows for greater transparency and administrative clarity, ensuring that suppliers, retailers, and healthcare providers can streamline imports of specialized items directly needed by patients.

From an economic perspective, regulatory precision within the U.S. customs code helps small medical supply businesses and independent pharmacies manage inventory without unexpected customs penalties or misclassification disputes. For consumers, lower administrative friction in supply chains often translates into broader product availability and stabilized retail pricing on out-of-pocket medical necessities.

Understanding the Harmonized Tariff Schedule

The Harmonized Tariff Schedule of the United States serves as the foundational regulatory document governing commercial imports into the country. Managed in conjunction with the U.S. International Trade Commission and enforced by U.S. Customs and Border Protection, the schedule assigns specific numerical codes to thousands of distinct commodities.

Chapter 39 of the tariff schedule primarily covers plastics and articles made from plastic compounds, including medical-grade silicone products. Chapter 90 broadly governs precision instruments, optical devices, medical and surgical equipment, and orthopedic or prosthetic appliances. By establishing discrete carve-outs within these two chapters, H.R. 10147 seeks to isolate items engineered explicitly for post-mastectomy recovery from unrelated general plastic products or standard apparel.

Proponents of targeted trade schedule revisions argue that clear classifications prevent specialized medical goods from being swept into sweeping general tariff actions, allowing policymakers to evaluate healthcare-related trade policies with greater accuracy.

Next Steps in the Legislative Process

Having been formally introduced in the House of Representatives, H.R. 10147 must navigate the committee review process before it can advance to the House floor for a broader vote. Because the measure involves modifications to federal customs statutes and import duties, it falls under the purview of congressional committees overseeing revenue and trade policy, most notably the House Committee on Ways and Means.

Should the bill secure committee approval, it would require passage by both the House and the Senate before being sent to the president to be signed into law. Lawmakers from across the political spectrum frequently evaluate targeted trade adjustments to assess their potential impacts on domestic manufacturing, federal customs administration, and patient healthcare costs across the country.